Comparison of the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia
10.3760/cma.j.issn.1008-6706.2015.03.017
- VernacularTitle:齐拉西酮与利培酮治疗精神分裂症的疗效及安全性比较
- Author:
Zhao ZHAO
;
Peixin LI
;
Yu ZHANG
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Ziprasidone;
Risperidone
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;22(3):370-372
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia.Methods According to the digital table,64 patients with schizophrenia were randomly divided into the two groups,32 cases in each group.The control group was given risperidone for treatment,while the observation group was given ziprasidone for treatment.The clinical efficacy was assessed by using the positive and negative symptom scale(PANSS),and adverse events were observed.Results The total effective rates of the control group and the observation group were 84.38％ and 87.50％,there was no significant difference between the two groups(x2 =2.66,P ＞ 0.05);The PANSS score and each factor score of the two groups after treatment decreased significantly than before treatment (t =8.11,7.86,7.72,7.90,6.77,6.58,7.52,7.40,all P ＜ 0.05),but there was no significant difference between the two groups (t =2.18,P ＞ 0.05) ;The incidence rate of adverse reaction of the observation group was 18.75％,which was significantly lower than 40.63％ of the control group (x2 =8.66,P ＜0.05).Conclusion Ziprasidone has therapeutic equivalence with risperidone in the treatment of schizophrenia,with less adverse reaction,high security,it has good clinical application value.
